Comparative Pharmacology
Head-to-head clinical analysis: SANSERT versus TRAZODONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SANSERT versus TRAZODONE HYDROCHLORIDE.
SANSERT vs TRAZODONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SANSERT (methysergide maleate) is a serotonin receptor antagonist, primarily acting on 5-HT2 receptors. It also has weak agonist activity at 5-HT1 receptors. The antimigraine effect is thought to be due to its vasoconstrictor properties and inhibition of neurogenic inflammation.
Trazodone hydrochloride is a triazolopyridine derivative with antidepressant activity. Its mechanism of action is not fully understood, but it is believed to involve inhibition of serotonin reuptake and antagonism at 5-HT2A and 5-HT2C receptors, as well as antagonism at alpha1-adrenergic and histamine H1 receptors.
2 mg orally three times daily; maximum 6 mg/day oral; typically started at 2 mg once daily and titrated over 2-4 weeks.
Initial 150 mg/day orally in divided doses, may increase by 50 mg/day every 3-4 days; usual range 150-400 mg/day; maximum 600 mg/day for inpatients.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours; clinical context: dosing every 8-12 hours maintains therapeutic levels.
5-9 hours (biphasic: alpha phase 3-6 min, beta phase 5-9 h); prolonged in elderly and hepatic impairment
Primarily hepatic metabolism with biliary excretion; ~4% excreted unchanged in urine; remainder as metabolites in feces.
Renal (70-75% as metabolites, <1% as parent drug); fecal (20-25%); biliary (minor)
Category C
Category A/B
Serotonin Antagonist
Serotonin Antagonist and Reuptake Inhibitor (SARI)